Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jul 6, 2026

Modeling Primary Bone Tumors and Bone Metastasis with Solid Tumor Graft Implantation into Bone
06:53

Modeling Primary Bone Tumors and Bone Metastasis with Solid Tumor Graft Implantation into Bone

Published on: September 9, 2020

PET/CT in malignant bone disease.

Einat Even-Sapir1

  • 1Department of Nuclear Medicine, Tel Aviv Sourasky Medical Center, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel. evensap@tasmc.health.gov.il

Seminars in Musculoskeletal Radiology
|March 8, 2008
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A novel tool to predict lymph node metastasis in patients with prostate cancer based on clinical and 68Ga-PSMA PET/CT parameters.

Canadian Urological Association journal = Journal de l'Association des urologues du Canada·2024
Same author

Prognostic significance of delayed complete metabolic response on PET/CT after primary chemoradiation treatment of cervical cancer.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2023
Same author

Staging Prostate Cancer with <sup>68</sup>Ga-PSMA-11 PET/CT in the Elderly: Is Preimaging Biopsy Imperative?

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2023
Same author

PET radiotracers for whole-body in vivo molecular imaging of prostatic neuroendocrine malignancies.

European radiology·2023
Same author

Beyond Visual Assessment of Basal Ganglia Uptake: Can Automated Method and Pineal Body Uptake Assessment Improve Identification of Nigrostriatal Dysfunction on <sup>18</sup>F-DOPA PET/CT?

International journal of molecular sciences·2023
Same author

A lesson in humility: the added values of PET-MRI over PET-CT in detecting malignant hepatic lesions.

European journal of nuclear medicine and molecular imaging·2023
Same journal

History of MSK Section of the Italian Society of Radiology.

Seminars in musculoskeletal radiology·2026
Same journal

Principles of Anatomy and Function in Wrist Imaging.

Seminars in musculoskeletal radiology·2026
Same journal

Opportunistic Screening Based on Computed Tomography in Musculoskeletal Radiology: How and Why.

Seminars in musculoskeletal radiology·2026
Same journal

Musculoskeletal Computed Tomography Imaging: A 30-Year Perspective.

Seminars in musculoskeletal radiology·2026
Same journal

Current Advances and Controversies in Spine Imaging.

Seminars in musculoskeletal radiology·2026
Same journal

New Techniques in Musculoskeletal MRI: State of the Art.

Seminars in musculoskeletal radiology·2026
See all related articles

Fluorine-18 fluorodeoxyglucose-positron emission tomography (18F-FDG-PET) effectively detects early bone marrow involvement in cancers. PET/CT imaging enhances diagnostic accuracy for malignant bone disease assessment.

Area of Science:

  • Nuclear medicine
  • Oncology
  • Radiology

Background:

  • Fluorine-18 fluorodeoxyglucose (18F-FDG) is a widely used PET tracer that accumulates in tumor cells.
  • 18F-FDG-PET can detect early bone marrow involvement before structural bone changes are visible.
  • Conventional bone scintigraphy may be replaced by 18F-FDG-PET for assessing malignant bone involvement.

Purpose of the Study:

  • To discuss the role of PET/CT, specifically 18F-FDG PET/CT, in evaluating malignant bone involvement.
  • To highlight the diagnostic advantages of 18F-FDG PET/CT over conventional methods.
  • To review its application in various cancers including sarcomas, solid malignancies, lymphoma, and multiple myeloma.

Main Methods:

  • Utilizing 18F-FDG as a PET tracer, a glucose analogue that enters tumor cells.

More Related Videos

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

Related Experiment Videos

Last Updated: Jul 6, 2026

Modeling Primary Bone Tumors and Bone Metastasis with Solid Tumor Graft Implantation into Bone
06:53

Modeling Primary Bone Tumors and Bone Metastasis with Solid Tumor Graft Implantation into Bone

Published on: September 9, 2020

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

  • Employing hybrid PET/CT systems for fused functional-anatomical imaging.
  • Assessing malignant bone involvement in diverse oncological patient cohorts.

    • Main Results:

    • 18F-FDG-PET demonstrates sensitivity for early detection of bone marrow metastasis.
    • Disappearance of 18F-FDG uptake post-therapy indicates successful treatment, irrespective of morphological changes.
    • PET/CT imaging improves diagnostic accuracy in identifying malignant bone infiltration.

    Conclusions:

    • 18F-FDG PET/CT is a valuable tool for assessing malignant bone involvement across various cancers.
    • The technique offers improved sensitivity and accuracy compared to conventional imaging.
    • It plays a crucial role in staging, treatment monitoring, and assessing therapeutic response.